Birdwatch Note
2023-11-02 16:58:45 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Ivermectin has no clinical studies in humans proving efficacy to treat cancer. Ivermectin has no efficacy to treat or prevent COVID-19 based on the results of randomized controlled trials https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362 https://jamanetwork.com/journals/jama/fullarticle/2777389 https://www.nejm.org/doi/full/10.1056/NEJMoa2115869 https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
Written by F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1720121889492717599
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1720123290268701002
- noteId - 1720123290268701002
- participantId -
- noteAuthorParticipantId - F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D Participant Details
- createdAtMillis - 1698944325392
- tweetId - 1720121889492717599
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Ivermectin has no clinical studies in humans proving efficacy to treat cancer. Ivermectin has no efficacy to treat or prevent COVID-19 based on the results of randomized controlled trials https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362 https://jamanetwork.com/journals/jama/fullarticle/2777389 https://www.nejm.org/doi/full/10.1056/NEJMoa2115869 https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-11-02 16:58:45 UTC (1698944325392) |
1969-12-31 23:59:59 UTC (-1) |
2023-11-04 03:04:16 UTC (1699067056450) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-11-03 17:34:49 -0500 | Rating Details | |
| 2023-11-03 12:41:01 -0500 | Rating Details | |
| 2023-11-03 12:08:26 -0500 | Rating Details | |
| 2023-11-03 11:09:48 -0500 | Rating Details | |
| 2023-11-03 10:50:19 -0500 | Rating Details | |
| 2023-11-03 10:11:43 -0500 | Rating Details | |
| 2023-11-03 10:09:52 -0500 | Rating Details | |
| 2023-11-03 09:40:26 -0500 | Rating Details | |
| 2023-11-03 09:27:22 -0500 | Rating Details | |
| 2023-11-03 08:30:47 -0500 | Rating Details | |
| 2023-11-03 08:26:41 -0500 | Rating Details | |
| 2023-11-03 08:02:38 -0500 | Rating Details | |
| 2023-11-03 06:48:24 -0500 | Rating Details | |
| 2023-11-03 06:44:43 -0500 | Rating Details | |
| 2023-11-03 06:41:43 -0500 | Rating Details | |
| 2023-11-03 06:24:12 -0500 | Rating Details | |
| 2023-11-03 06:03:01 -0500 | Rating Details | |
| 2023-11-03 05:53:48 -0500 | Rating Details | |
| 2023-11-03 05:31:54 -0500 | Rating Details | |
| 2023-11-03 05:15:49 -0500 | Rating Details | |
| 2023-11-03 05:12:04 -0500 | Rating Details | |
| 2023-11-03 04:56:46 -0500 | Rating Details | |
| 2023-11-03 02:32:01 -0500 | Rating Details | |
| 2023-11-03 01:33:08 -0500 | Rating Details | |
| 2023-11-03 01:14:59 -0500 | Rating Details | |
| 2023-11-03 01:12:10 -0500 | Rating Details | |
| 2023-11-03 00:36:00 -0500 | Rating Details | |
| 2023-11-03 00:25:22 -0500 | Rating Details | |
| 2023-11-02 23:10:33 -0500 | Rating Details | |
| 2023-11-02 23:00:47 -0500 | Rating Details | |
| 2023-11-02 22:00:04 -0500 | Rating Details | |
| 2023-11-02 21:21:03 -0500 | Rating Details | |
| 2023-11-02 21:20:33 -0500 | Rating Details | |
| 2023-11-02 21:11:13 -0500 | Rating Details | |
| 2023-11-02 20:39:05 -0500 | Rating Details | |
| 2023-11-02 20:33:27 -0500 | Rating Details | |
| 2023-11-02 20:29:01 -0500 | Rating Details | |
| 2023-11-02 19:52:01 -0500 | Rating Details | |
| 2023-11-02 19:50:10 -0500 | Rating Details | |
| 2023-11-02 19:34:53 -0500 | Rating Details | |
| 2023-11-02 19:22:18 -0500 | Rating Details | |
| 2023-11-02 19:12:20 -0500 | Rating Details | |
| 2023-11-02 19:11:10 -0500 | Rating Details | |
| 2023-11-02 19:08:27 -0500 | Rating Details | |
| 2023-11-02 19:06:05 -0500 | Rating Details | |
| 2023-11-02 18:47:59 -0500 | Rating Details | |
| 2023-11-02 18:45:24 -0500 | Rating Details | |
| 2023-11-02 18:22:50 -0500 | Rating Details | |
| 2023-11-02 17:42:48 -0500 | Rating Details | |
| 2023-11-02 17:40:31 -0500 | Rating Details | |
| 2023-11-02 17:32:19 -0500 | Rating Details | |
| 2023-11-02 17:10:29 -0500 | Rating Details | |
| 2023-11-02 17:06:25 -0500 | Rating Details | |
| 2023-11-02 17:05:32 -0500 | Rating Details | |
| 2023-11-02 16:39:36 -0500 | Rating Details | |
| 2023-11-02 15:41:39 -0500 | Rating Details | |
| 2023-11-02 15:39:05 -0500 | Rating Details | |
| 2023-11-02 15:29:05 -0500 | Rating Details | |
| 2023-11-02 15:26:58 -0500 | Rating Details | |
| 2023-11-02 15:23:58 -0500 | Rating Details | |
| 2023-11-02 15:20:06 -0500 | Rating Details | |
| 2023-11-02 15:17:52 -0500 | Rating Details | |
| 2023-11-02 14:54:44 -0500 | Rating Details | |
| 2023-11-02 14:33:24 -0500 | Rating Details | |
| 2023-11-02 14:22:25 -0500 | Rating Details | |
| 2023-11-02 14:03:06 -0500 | Rating Details | |
| 2023-11-02 13:59:29 -0500 | Rating Details | |
| 2023-11-02 13:51:46 -0500 | Rating Details | |
| 2023-11-02 13:45:54 -0500 | Rating Details | |
| 2023-11-02 13:36:31 -0500 | Rating Details | |
| 2023-11-02 13:33:55 -0500 | Rating Details | |
| 2023-11-02 13:24:41 -0500 | Rating Details | |
| 2023-11-02 12:15:10 -0500 | Rating Details | |
| 2023-11-02 12:09:45 -0500 | Rating Details | |
| 2023-11-02 12:05:04 -0500 | Rating Details | |
| 2023-11-02 12:03:21 -0500 | Rating Details | |
| 2023-11-02 12:02:19 -0500 | Rating Details | |
| 2023-11-02 12:01:58 -0500 | Rating Details | |
| 2023-11-02 12:01:04 -0500 | Rating Details | |
| 2023-11-04 19:08:43 -0500 | Rating Details | |
| 2023-11-04 18:44:03 -0500 | Rating Details | |
| 2023-11-04 17:59:18 -0500 | Rating Details | |
| 2023-11-04 17:08:40 -0500 | Rating Details | |
| 2023-11-04 16:53:25 -0500 | Rating Details | |
| 2023-11-04 16:22:40 -0500 | Rating Details | |
| 2023-11-04 16:01:01 -0500 | Rating Details | |
| 2023-11-04 15:50:59 -0500 | Rating Details | |
| 2023-11-04 15:26:14 -0500 | Rating Details | |
| 2023-11-04 15:12:49 -0500 | Rating Details | |
| 2023-11-04 14:56:56 -0500 | Rating Details | |
| 2023-11-04 14:19:00 -0500 | Rating Details | |
| 2023-11-04 14:17:49 -0500 | Rating Details | |
| 2023-11-04 13:40:45 -0500 | Rating Details | |
| 2023-11-04 12:12:20 -0500 | Rating Details | |
| 2023-11-04 12:11:13 -0500 | Rating Details | |
| 2023-11-04 11:42:52 -0500 | Rating Details | |
| 2023-11-04 11:25:53 -0500 | Rating Details | |
| 2023-11-04 11:25:27 -0500 | Rating Details | |
| 2023-11-04 11:19:16 -0500 | Rating Details | |
| 2023-11-04 11:13:03 -0500 | Rating Details | |
| 2023-11-03 21:21:40 -0500 | Rating Details | |
| 2023-11-05 09:35:41 -0600 | Rating Details | |
| 2023-11-05 08:45:17 -0600 | Rating Details | |
| 2023-11-05 01:15:47 -0500 | Rating Details | |
| 2023-11-04 23:55:12 -0500 | Rating Details | |
| 2023-11-04 22:22:05 -0500 | Rating Details | |
| 2023-11-04 20:39:19 -0500 | Rating Details | |
| 2023-11-13 09:20:35 -0600 | Rating Details | |
| 2023-11-17 16:17:01 -0600 | Rating Details | |
| 2023-11-27 04:31:36 -0600 | Rating Details | |
| 2024-03-24 13:11:12 -0500 | Rating Details | |
| 2024-08-03 13:30:43 -0500 | Rating Details | |
| 2024-08-03 00:55:57 -0500 | Rating Details | |
| 2024-08-02 15:15:50 -0500 | Rating Details | |
| 2024-08-02 14:43:55 -0500 | Rating Details |